Will Valeant Change Its Drug-Pricing Practices?

The transcript discusses a hearing where an investor with a notable career admits to insufficient due diligence in drug pricing. Valeant's strategy of acquiring old drugs and significantly raising prices is examined, highlighting the lack of generic competition. Testimonies reveal a shift in attitude, acknowledging unjustified price hikes. A case study on heart medications shows extreme price increases, suggesting greed as a motive.

What did the analysis suggest about the price increase of heart medications?

What conclusion can be drawn from Valeant's decision to increase prices significantly?